Phase 4 N=167 Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Fuchs' Dystrophy · Corneal Edema
Primary: Intraocular Pressure — 11; 27 eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Corneal Neovascularization · Corneal Graft Failure
Primary: Number of Participants With Graft Failure at Week 39 and 52 — 0; 1; 1; 1 Participants
Phase 4 N=70 Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Corneal Endothelial Dystrophy · Corneal Edema
Primary: Immunologic Rejection — 0 Participants
Phase 3 N=191 Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
Fuchs' Endothelial Dystrophy · Bullous Keratopathy
Primary: Intraocular Pressure — 11; 18 Participants
N/A N=5 Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Corneal Ulcer · Leukoma
Primary: Incidence of Treatment-Emergent Adverse Events — 0 events
Phase 2 N=264 Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
Fuchs' Dystrophy · Bullous Keratopathy
Primary: Number of Eyes With Immunologic Graft Rejection Episodes — 2; 0 eyes — p=0.17
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
N/A N=1,090 Cornea Donor Study
Corneal Disease · Fuch's Dystrophy · Pseudophakic Corneal Edema
Primary: Graft Failure — 142; 82 participants
N/A N=1,274 Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
Corneal Endothelial Decompensation · Fuchs' Endothelial Dystrophy
Primary: Graft Failure — 32; 15 eyes
Phase 4 N=1,405 Cornea Preservation Time Study
Cornea Preservation Time · Endothelial Keratoplasty · Transplant Success
Primary: Number of Eyes With Corneal Graft Failure Within 3 Years of Surgery — 30; 49 Eyes — p=0.02
Phase 2 N=75 A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Corneal Neovascularization · Corneal Graft Failure
Primary: Endothelial Rejection Rate — 2; 5 Participants — p=0.10
N/A N=40 Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
Fuchs Endothelial Dystrophy · Corneal Edema
Primary: Endothelial Cell Loss — 28; 36 percentage of endothelial cell loss — p=0.10
N/A N=94 Simultaneous TransPRK and Corneal Collagen Cross-Linking
Keratoconus
Primary: Change in LogMAR Corrected Distance Visual Acuity (CDVA) — -0.13; -0.05 LogMAR CDVA — p=0.03
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
Phase 3 N=147 Cross-linking for Corneal Ulcers Treatment Trial
Corneal Ulcer · Infectious Keratitis · Bacterial Ulcer
Primary: Microbiological Cure on Repeat Culture — 5; 5; 17; 14 Participants
Phase 1 N=165 Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Corneal Epithelial Defect · Diabetic Retinopathy · Penetrating Keratoplasty
Primary: Patients With Corneal Epithelial Healing Time Within 14 Days — 78; 73 participants
Phase 3 N=130 Corneal Collagen Cross-Linking for Ectasia (CXL)
Ectasia
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -0.5; 0.5 diopters
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 4 N=20 Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study
Keratoconus, Unstable · Collagen Crosslinking · Postoperative Pain
Primary: Change in Degree of Postoperative Pain Between Groups From Date of Surgery Through 1 Month Post-CXL (Day of Surgery, Postoperative Days 1 ,3, 7, Postoperative Weeks 2 ,3…
Phase 2 N=1 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Phase 2 N=33 Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
Chronic Ocular Graft-versus-host Disease
Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197
Phase 3 N=64 Life 4°C Versus Optisol in Corneal Storage Media
Complications of Corneal Transplant
Primary: Endothelial Cell Loss Post EK for Donor Corneas Preserved in Life 4°C and Optisol GS Corneal Storage Media — 20; 18 % endothelial cell loss — p=< 0.05
N/A N=21 Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) — 1; 3; 7; 9 Participants
Phase 4 N=131 Loteprednol vs. Prednisolone and Fluorometholone
Intraocular Pressure · Corneal Opacity
Primary: Change in Intraocular Pressure (IOP) From Baseline Through Month 3 — 14.38; 14.30; 13.67; 13.28 mmHg
Phase 2 N=20 Treatment of Corneal Neovascularization With Topical Pazopanib
Corneal Neovascularization
Primary: Heart Rate — 68.7 Beats per Minutes
Phase 3 N=164 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Leukemia
Primary: Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo) — 9; 8 participants — p=>0.99
Phase 4 N=59 Use of Bevacizumab in Trabeculectomy Surgery
Glaucoma · Optic Neuropathy · Fibrosis
Primary: Intraocular Pressure — 13.9; 13.2 mm Hg — p=<0.05
N/A N=75 Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Dry Eyes
Primary: Progression of Dry Eye Severity — 15; 12 patients with increased dry eye severity
N/A N=135 Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
Keratoconus
Primary: Number of Participants With Complete Healing of Corneal Epithelial Defect at Day 3 — 20; 25 Participants